MetaCap

Cogent Biosciences (COGT) vs Liquidia (LQDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Liquidia (LQDA) has outperformed Cogent Biosciences (COGT) over the past year, gaining 87.0% versus a loss of 27.3%. Over five years, LQDA leads with a +1224.3% price change compared with +219.6% for COGT. Liquidia is the larger company by market cap ($4.90 billion vs $4.65 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COGT-27.33%LQDA+86.98%
+225%+93%-39%
Nov 21, 20251 yearNov 20, 2026
COGT+172.60%LQDA+1177.70%
+2122%+980%-162%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COGT versus LQDA key metrics
MetricCOGTLQDA
Share price$26.72$54.43
Market cap$4.65B$4.90B
1-day change-3.70%-3.88%
YTD return-24.79%+57.81%
1-year return-27.33%+86.98%
5-year return+219.56%+1224.33%
Forward P/E—15.12
EPS (TTM)$-2.26$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$158.32M
Revenue growth (YoY)—+1031.18%
Net income (latest FY)$-328.94M$-68.92M
Operating margin—-32.45%
Net margin—-43.53%
52-week high$43.73$93.61
52-week low$26.36$22.31
Distance from 52-week high-38.91%-41.85%
Analyst consensusstrong_buybuy
Avg. price target upside+108.95%+21.50%
Average volume2.07M3.52M
Shares outstanding173.99M90.11M
Employees258216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LQDA has outperformed COGT by 114.3 percentage points over the past year.

About Cogent Biosciences

COGT stock →

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees

About Liquidia

LQDA stock →

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

COGT vs LQDA FAQ

Which is bigger, Cogent Biosciences or Liquidia?

Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.65B for Cogent Biosciences (COGT).

Which stock has performed better over the past year, COGT or LQDA?

LQDA returned +86.98% over the past 12 months, compared with -27.33% for COGT (price return, excluding dividends). Past performance does not predict future results.

Are Cogent Biosciences and Liquidia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons